📇 Rhumatologue · PARIS · (75) · Salarié

MME Catherine GANEM-ALBOU

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
En plein centre-ville
PARIS (75008) — accessible depuis tout le bassin urbain
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS (75)SalariéRPPS 10000426329

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

DR ALBOU-GANEM CATHERINE
230 RUE DU FAUBOURG SAINT HONORE, 75008 PARIS
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer

Discover nano · 2025

📚 6 citations🎯 RCR 2.16🔓 Open Access📄 PDF gratuit ↗

Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program

Journal of leukocyte biology · 2024

📚 4 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Mepolizumab, an anti-interleukin-5 antibody, has been proven a safe and effective glucocorticoid (GC)-sparing drug for many patients with nonclonal hypereosinophilic syndrome (HES) and is now approved in many countries. It remains unclear, however, which patients are most likely to benefit from therapy and whether the currently approved dosing regimen is appropriate for all. This observational retrospective study included all patients with HES who were enrolled in the MHE104317 compassionate use program (CUP) in our center. Patient and disease characteristics, mepolizumab dosing, and both clinical and hematological responses to treatment were collected from medical files. Treatment responses and mepolizumab dosing requirements were analyzed according to disease characteristics. Eighteen patients with HES were enrolled in the CUP, of whom nine are still on treatment. The median duration of exposure to mepolizumab was 45 mo (maximum 18 yr). A lower number of affected organs, requirement for GC dosing ≤10 mg prednisone-equivalent, and single-organ HES were associated with a higher likelihood of complete response. Lymphocytic variant HES (L-HES) was less treatment-responsive, leading to withdrawal and/or requiring higher mepolizumab dosing to achieve some degree of disease control. In contrast, all patients with single-organ disease had a complete response that could often be maintained despite increasing between-dose intervals. Few potentially treatment-related adverse events were observed despite prolonged exposure. This study confirms the efficacy and safety of mepolizumab in HES, although patients with L-HES rarely experience a complete response. In contrast, patients with single-organ disease affecting the lungs are often super-responders, and decreasing mepolizumab dosing may be attempted.

Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A multicenter prospective study

The Journal of allergy and clinical immunology · 2025

📚 3 citations🩺 Clinique🔓 Open Access

Cookies & analyse de trafic

MME Catherine GANEM-ALBOU

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (27) — classées par pathologie

Transversal8

Pédiatrie4

Case report / série3

Revue générale3

Santé mentale / fatigue3

Essai clinique2

Revue / méta-analyse2

Vraie vie / RWE2

Activité physique / Rééducation1

Corticothérapie1

Économie santé1

Épidémiologie & registres1

Gériatrie1

Lupus1

Pharmacovigilance1

SAPL1

Vascularites des gros vaisseaux1

Partager cette fiche